Asklepion Pharmaceuticals
Manufacturing · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
729 E Pratt St Ste 360, Baltimore, Maryl...Phone Number
(410) 545-0494Website
www.asklepionpharm.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Asklepion Pharmaceuticals
Asklepion Pharmaceuticals, LLC is a pharmaceutical development company dedicated to the discovery, development, and commercialization of products aimed at patients with rare diseases, particularly children who have limited therapeutic options. The company focuses on innovative treatments, including intravenous citrulline for pediatric patients undergoing cardiopulmonary bypass. Asklepion has received recognition for its contributions to rare disease treatment, including Orphan Drug Designation from the U.S. FDA. Their mission is to provide effective treatment options for those affected by rare conditions.Explore more
Asklepion Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Asklepion Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Asklepion Pharmaceuticals recently announced quarterly report
Click to see if Asklepion Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Asklepion Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Asklepion Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Asklepion Pharmaceuticals has new funding data
Check out if Asklepion Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Asklepion Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Asklepion Pharmaceuticals
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Asklepion Pharmaceuticals
Compare insights from companies similar to Asklepion Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Asklepion Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Asklepion Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Asklepion Pharmaceuticals.
Asklepion Pharmaceuticals Tech Stack
A closer look at the technologies used by Asklepion Pharmaceuticals
See more technologies
Asklepion Pharmaceuticals News & Media
Asklepion Pharmaceuticals concludes enrollment of Phase III trial: L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects
BALTIMORE, July 01, 2019 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”), a biotechnology company focused on the development of novel therapeutics for rare pediatric diseases, today announced the completion of enrollment of its Phase III double-blind, randomized, placebo controlled, multi-center clinical study to evaluate the efficacy and safety of intravenous L-citrulline for the prevention of clinical sequelae of acute lung injury induced by cardiopulmonary byKey Patent Coverage for Asklepion Pharmaceuticals’ Investigational Candidate Extended to 2036
BALTIMORE, April 26, 2019 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”), a biotechnology company focused on the development of novel therapeutics for rare pediatric diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent 10,265,286, titled: “Sequelae of Cardiopulmonary Bypass-Induced Pulmonary Injury.” The patent covers a method for using IV-Citrulline to maintain the coupling of endothelial nitric oxide synthaAsklepion Pharmaceuticals Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Program of Intravenous Citrulline
BALTIMORE, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”) announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for intravenous citrulline. This SPA provides agreement that the Phase 3 protocol design, notably clinical endpoints, trial population and statistical analyses adequately address objectives that, if met, would formAsklepion Pharmaceuticals Presents Phase 1b/2a Clinical Trial Data for IV-Citrulline at the Pediatric Cardiac Intensive Care Society 13th Annual International Meeting
BALTIMORE, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”), a biotechnology company focused on the development of IV-citrulline for rare pediatric diseases, announced detailed results from a Phase 1b/2a double blind, randomized, placebo controlled, clinical trial to determine the pharmacokinetics and safety of a revised protocol of intravenous citrulline versus placebo in children undergoing cardiopulmonary bypass (CPB). The data was presented at t
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Asklepion Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Asklepion Pharmaceuticals, LLC is a pharmaceutical development company dedicated to the discovery, development, and commercialization of products aimed at patients with rare diseases, particularly children who have limited therapeutic options. The company focuses on innovative treatments, including intravenous citrulline for pediatric patients unde... Read More
